These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30355278)

  • 1. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma.
    Borg D; Hedner C; Nodin B; Larsson A; Johnsson A; Eberhard J; Jirström K
    BMC Clin Pathol; 2016; 16():13. PubMed ID: 27478410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
    Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
    Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
    Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
    J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma.
    Sisic L; Blank S; Nienhüser H; Haag GM; Jäger D; Bruckner T; Ott K; Schmidt T; Ulrich A
    Surg Oncol; 2020 Jun; 33():177-188. PubMed ID: 28684226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podocalyxin as a Prognostic Marker in Gastric Cancer.
    Laitinen A; Böckelman C; Hagström J; Kokkola A; Fermér C; Nilsson O; Haglund C
    PLoS One; 2015; 10(12):e0145079. PubMed ID: 26674770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
    Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
    Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases.
    Larsson AH; Nodin B; Syk I; Palmquist I; Uhlén M; Eberhard J; Jirström K
    Diagn Pathol; 2013 Jul; 8():109. PubMed ID: 23819542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
    Larsson A; Fridberg M; Gaber A; Nodin B; Levéen P; Jönsson G; Uhlén M; Birgisson H; Jirström K
    BMC Cancer; 2012 Jul; 12():282. PubMed ID: 22769594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
    Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
    Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.
    He S; Du W; Li M; Yan M; Zheng F
    BMC Cancer; 2020 Jul; 20(1):620. PubMed ID: 32615943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
    Larsson A; Johansson ME; Wangefjord S; Gaber A; Nodin B; Kucharzewska P; Welinder C; Belting M; Eberhard J; Johnsson A; Uhlén M; Jirström K
    Br J Cancer; 2011 Aug; 105(5):666-72. PubMed ID: 21829192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.